A Phase 2, Randomized, Crossover Study to Evaluate the Effect of Intranasal Insulin and NovoLog on Postprandial Glycemic Control in Type 2 Diabetic Patients

Trial Profile

A Phase 2, Randomized, Crossover Study to Evaluate the Effect of Intranasal Insulin and NovoLog on Postprandial Glycemic Control in Type 2 Diabetic Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Jun 2008

At a glance

  • Drugs Insulin; Insulin aspart
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors Marina Biotech
  • Most Recent Events

    • 10 Jun 2008 Primary endpoint met; results were reported at the 68th Scientific Sessions of the American Diabetes Association according to a Nastech Pharmaceutical media release.
    • 10 Jun 2008 Status changed from in progress to completed according to Nastech Pharmaceutical Company.
    • 15 Apr 2008 Status changed from recruiting to in progress according to ClincialTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top